Jane Pritchett Henderson - 09 Dec 2025 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Director
Signature
/s/ Jonathan Young, Attorney-in-Fact
Issuer symbol
AKRO
Transactions as of
09 Dec 2025
Net transactions value
$0
Form type
4
Filing time
09 Dec 2025, 10:06:19 UTC
Previous filing
05 Dec 2025
Next filing
23 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Henderson Jane Director C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO /s/ Jonathan Young, Attorney-in-Fact 09 Dec 2025 0001422304

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Disposed to Issuer -9,398 -100% 0 09 Dec 2025 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Disposed to Issuer -26,000 -100% 0 09 Dec 2025 Common Stock 26,000 $23.02 Direct F4
transaction AKRO Stock Option (Right to Buy) Disposed to Issuer -15,000 -100% 0 09 Dec 2025 Common Stock 15,000 $50.83 Direct F4
transaction AKRO Stock Option (Right to Buy) Disposed to Issuer -15,000 -100% 0 09 Dec 2025 Common Stock 15,000 $8.13 Direct F4
transaction AKRO Stock Option (Right to Buy) Disposed to Issuer -13,000 -100% 0 09 Dec 2025 Common Stock 13,000 $26.32 Direct F4
transaction AKRO Stock Option (Right to Buy) Disposed to Issuer -13,000 -100% 0 09 Dec 2025 Common Stock 13,000 $25.20 Direct F4
transaction AKRO Stock Option (Right to Buy) Disposed to Issuer -11,797 -100% 0 09 Dec 2025 Common Stock 11,797 $7.01 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Jane Pritchett Henderson is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 9, 2025 (such date and time, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo.
F2 Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of common stock of the Issuer ("Company Common Stock") upon vesting of the Company RSU.
F3 Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive in respect of each such Company RSU (i) cash in an amount equal to $54.00 (the "Closing Consideration") and (ii) one contractual contingent value right (a "CVR") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement), without interest and subject to any withholding taxes.
F4 Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.